干燥病相关黏膜相关淋巴组织淋巴瘤预测因素的识别及其随时间演变:一项病例对照研究
这项病例对照研究纳入三个中心、至少间隔3年诊断为干燥病相关黏膜相关淋巴组织(MALT)淋巴瘤的患者,并按1:1匹配无淋巴瘤的干燥病患者作为对照,构建三个时间点数据集以识别MALT淋巴瘤预测因素。结果发现,类风湿因子是干燥病诊断时唯一独立预测因素(OR 3.33),而在淋巴瘤诊断前3-4年,类风湿因子(OR 3.66)和EULAR干燥综合征疾病活动指数≥5(OR 3.88)为独立危险因素。
要点
- 类风湿因子是干燥病相关MALT淋巴瘤最早且持续存在的独立预测因素。
- 淋巴瘤诊断前3-4年,EULAR干燥综合征疾病活动指数≥5为独立危险因素。
- 从干燥病诊断至淋巴瘤诊断前3-4年期间的高疾病活动度归因于冷球蛋白血症及腺体、皮肤和血液学等B细胞相关表现。
核心结论
- 基于预测因素的时间演变对干燥病相关MALT淋巴瘤高危患者进行随访,为早期诊断和潜在治疗干预提供了机会。
- 类风湿因子是淋巴瘤最早且最持久的独立预测因素。
- 特定B细胞表现联合类风湿因子提示淋巴瘤发生过程处于更晚期阶段。
研究设计与样本
- 病例对照研究,纳入来自三个干燥病专科中心(希腊雅典大学、意大利比萨大学、意大利乌迪内大学)的干燥病相关MALT淋巴瘤患者,要求干燥病诊断与MALT淋巴瘤诊断之间至少间隔3年。
- 对照为无淋巴瘤的干燥病患者,按年龄、性别、末次随访时疾病病程和治疗方式1:1匹配。
- 构建三个协调数据集,分别代表淋巴瘤发生进展的三个不同时间点:V1为干燥病诊断时,V2为淋巴瘤诊断前3-4年,V3为淋巴瘤诊断前0.5-1.5年。
- 所有纳入患者均符合2016年美国风湿病学会-欧洲抗风湿病联盟干燥病分类标准。
- 采用基于快速相关性的特征选择和逻辑回归模型在V1和V2时间点识别MALT淋巴瘤预测因素。
主要发现
- V1数据集纳入80例干燥病相关MALT淋巴瘤患者,V2数据集纳入68例,V3数据集纳入80例,并与无淋巴瘤的干燥病对照匹配。
- 两组中,80例参与者中72例(90%)为女性,8例(10%)为男性。
- 淋巴瘤组干燥病诊断时平均年龄为48.6岁(SD 11.6),对照组为48.7岁(11.5)。
- 所有患者均为白人,160例中88例(55%)为希腊国籍,72例(45%)为意大利国籍。
- 在V1时间点,类风湿因子是唯一独立淋巴瘤预测因素(比值比3.33 [95% CI 1.96-5.64])。
关键数值与推荐
- V1时间点:类风湿因子比值比3.33(95% CI 1.96-5.64)。
- V2时间点:类风湿因子比值比3.66(95% CI 2.08-6.42)。
- V2时间点:欧洲抗风湿病联盟干燥综合征疾病活动指数≥5比值比3.88(95% CI 1.69-8.90)。
- 所有患者符合2016年美国风湿病学会-欧洲抗风湿病联盟干燥病分类标准。
临床怎么用
- 原文未据此给出推荐。
局限性
- 组织学参数未纳入分析。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Non-Hodgkin lymphomas have a substantial impact on individuals with Sjögren's disease. This study focuses on mucosal-associated lymphoid tissue (MALT) lymphomas, which constitute the majority of Sjögren's disease-associated non-Hodgkin lymphomas. We aimed to identify reliable lymphoma predictors in patients with Sjögren's disease and study their progression over time. METHODS: In this case-control study, patients diagnosed with Sjögren's disease-associated MALT lymphoma, with a minimum of 3 years between Sjögren's disease diagnosis and MALT lymphoma diagnosis, were included from three centres specialising in Sjögren's disease (University of Athens, Athens, Greece; University of Pisa, Pisa, Italy; and University of Udine, Udine, Italy) and matched 1:1 with control participants with Sjögren's disease who did not have lymphoma according to age, sex, disease duration at last follow up, and treatment modality. Three harmonised datasets were constructed, curated, and analysed to identify MALT lymphoma predictors, representing three distinct timepoints in lymphomagenesis progression: V1 at Sjögren's disease diagnosis, V2 3-4 years before lymphoma diagnosis, and V3 0·5-1·5 years before lymphoma diagnosis. All recruited patients fulfilled the 2016 American College of Rheumatology-European League Against Rheumatism criteria for Sjögren's disease. The primary outcome was to identify MALT lymphoma predictors in Sjögren's disease, present at the timepoint of Sjögren's disease diagnosis and 3-4 years before the diagnosis of MALT lymphoma. A fast correlation-based feature selection and logistic regression model was used at V1 and V2 to identify MALT lymphoma predictors. The progression of potential predictors was studied across V1, V2, and V3. Histological parameters were not included in the analysis. An individual with lived experience of Sjögren's disease was involved in the study design. FINDINGS: 80 patients with Sjögren's disease-associated MALT lymphoma were included in the V1 dataset, 68 in the V2 dataset, and 80 in the V3 dataset, and matched to control participants with Sjögren's disease who did not have lymphoma. In both groups, 72 (90%) of 80 participants were women and eight (10%) were men. The mean age at Sjögren's disease diagnosis was 48·6 years (SD 11·6) in the lymphoma group and 48·7 years (11·5) in the control group. All patients were White, with 88 (55%) of 160 individuals of Greek nationality and 72 (45%) of Italian nationality. At the V1 timepoint, rheumatoid factor was the only independent lymphoma predictor (odds ratio 3·33 [95% CI 1·96-5·64]). At the V2 timepoint, rheumatoid factor (3·66 [95% CI 2·08-6·42]) and European League Against Rheumatism Sjögren's Syndrome Disease Activity Index ≥5 (3·88 [1·69-8·90]) were identified as independent lymphoma risk factors. The high disease activity during the transition from the V1 to V2 timepoint was attributed to specific B-cell-derived manifestations, including cryoglobulinaemia and glandular, cutaneous, and hematological manifestations. INTERPRETATION: Following up patients with high-risk of Sjögren's disease-associated MALT lymphoma based on the temporal progression of predictors presents an opportunity for early diagnosis and potential therapeutic interventions. Rheumatoid factor was the earliest and most persistent independent predictor of lymphoma. Specific B-cell manifestations in combination with rheumatoid factor indicate a more advanced stage of the lymphomagenesis process. FUNDING: European Commission-Horizon 2020.
引用
- Goules AV, Chatzis L, Pezoulas VC, et al. Identification and evolution of predictors of Sjögren's disease-associated mucosa-associated lymphoid tissue lymphoma development over time: a case-control study. Lancet Rheumatol. 2024. PMID: 39182505. doi:10.1016/S2665-9913(24)00183-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。